Tau positron emission tomographic imaging in aging and early Alzheimer disease - Wikidata - awgldk - TriplyDB

Tau positron emission tomographic imaging in aging and early Alzheimer disease

Tau positron emission tomographic imaging in aging and early Alzheimer disease

http://www.wikidata.org/entity/Q36535275

about

Untangling tau imaging A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers Characteristics of Tau and Its Ligands in PET Imaging Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex.Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy.Future Directions in Imaging Neurodegeneration.Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance.Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease Tumor necrosis factor α Inhibition for Alzheimer's Disease.Tau PET imaging: present and future directions.Screening for mild cognitive impairment: If not now, when?Labeling Pathological Tau: An Important Quest for the Unknown.Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain.An Alzheimer's Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults.18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease Therapy and clinical trials in frontotemporal dementia: past, present, and future.A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease.Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.Repetitive head impact exposure and later-life plasma total tau in former National Football League players.PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.Distinct white matter injury associated with medial temporal lobe atrophy in Alzheimer's versus semantic dementia.PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure.Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study.Alzheimer Disease: Scientific Breakthroughs and Translational Challenges.Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.Mapping Neurodegenerative Disease Onset and Progression.Defining imaging biomarker cut points for brain aging and Alzheimer's disease.Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.Molecular and cellular pathophysiology of preclinical Alzheimer's disease.Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals.

P2860

Q26739091-25A3296D-CB20-42EA-BEEE-507EFA9BA01F Q26745508-1EAF8B6E-1C81-4AD7-8189-3B09FD175221 Q26769952-C7D3C010-CC40-4C54-9E90-142A9767F559 Q30100986-354F0813-21A8-431E-807D-DE67F0AA6667 Q30275833-87CE1CA5-2617-46B9-A914-2C6B2D68CB93 Q31162702-23E8E6FB-4209-4422-804A-924880A6C848 Q33563786-ABA1A5FD-00D8-4B2C-BEAD-A0CFBEEFEDB1 Q33695122-76A0210B-5C2D-4858-B8FF-C5A2F8B25DB3 Q33704278-EAC99BD6-56AC-49E0-9CA0-0B3FCC960715 Q34680852-048B2605-6192-4804-962F-4D7B761EF4C9 Q36415014-8FC1FC9A-3E9D-43CB-A97D-96AF8AA6C6EE Q36970036-CEC2857F-0389-4560-99BA-5C3B09867DB8 Q37063163-C2B22833-2AE2-4164-A414-F643BE92D468 Q37096041-88ABAA68-D59F-4C9C-ABD5-83013125F716 Q37096748-4ACDCB36-1FD7-4E3C-B41F-48EC052A9CFF Q37198563-12E4E4C9-CA83-4F7C-9BED-88525A8D524B Q37220632-AB86B7CA-B693-48AF-97CF-1ACA9D4011BE Q37294936-2976C789-6DFD-41A2-A54C-D0D3EA874AD4 Q37566888-990189D3-FA33-4448-BE6D-D93EBCF186FF Q37590389-93E5E9D5-6158-4B1E-BC55-8E5AF2703498 Q37600680-054DD821-9C8D-4900-BC31-808642F451DA Q37633577-D7163077-B0C3-4C76-8E3E-77707DE8AB4E Q37645272-3792D525-CF2D-4E10-8475-659C44032D9C Q37718557-1712559A-C41B-4129-9964-313426339326 Q37731710-5AD7DD3C-6E08-4D35-8996-F96AD8689F95 Q37731919-EB140EB8-4AFA-436B-B01A-AE71409CCBA8 Q37739881-BC53B4FE-D885-48DA-A6B6-6441FC2671EA Q37739887-862086B3-608A-48E1-8752-4DD4FCA2264F Q38383420-3F4187D6-A52D-414F-9046-76AAC27E6C45 Q38628805-D1FBEAE2-B1D4-42D2-BC24-F07083716DDE Q38640294-CBE7EF96-275A-4A1D-A19A-941CFDD00F3B Q38653494-EBE6BB94-AB1D-4E3E-B3C4-0C909FFA01F8 Q38659171-68CFA878-9435-4808-98F7-4900F7DE26C0 Q38675107-E2A5288E-05F6-4A2B-B7D6-020958477EE4 Q38739937-F5229C1B-9663-4752-B244-8347DA8FC257 Q38746445-613E2525-E606-4DD7-8B2A-D229F1964BCB Q38803637-3C247EB4-3658-4D95-8A41-9F15ECE03F12 Q38812890-D3BB6228-E061-4C21-9E82-1AF7FCC5388F Q38836004-45C96DE9-CE82-4E18-982C-FB68D2B4A43E Q38896981-AD1D0BF8-25D9-4E6C-A6E6-18BF0FB32FA6

P2860

Tau positron emission tomographic imaging in aging and early Alzheimer disease

http://www.wikidata.org/entity/Q36535275

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Tau positron emission tomographic imaging in aging and early Alzheimer disease

@ast

Tau positron emission tomographic imaging in aging and early Alzheimer disease

@en

type

label

Tau positron emission tomographic imaging in aging and early Alzheimer disease

@ast

Tau positron emission tomographic imaging in aging and early Alzheimer disease

@en

prefLabel

Tau positron emission tomographic imaging in aging and early Alzheimer disease

@ast

Tau positron emission tomographic imaging in aging and early Alzheimer disease

@en

P1433

Q36535275-F8466D98-66D4-4ED3-B37F-FAD4B5713BB1

P1476

Q36535275-0EBC4E8D-C3A0-4CCC-AE4A-F570F1050227

P2093

Q36535275-14C5EFAF-34C0-4183-B3D6-492D2059350D

Q36535275-18732B4F-D24C-40BC-9E69-71D4B6AF2BEB

Q36535275-2CDEBA35-19CC-47B1-A11C-A5BAF2B427C7

Q36535275-3378007E-D808-45AE-AF0F-987FB1042C89

Q36535275-52397965-418B-4043-ADFE-96321159F388

Q36535275-54698D6D-02C1-4406-9BAD-168646D3A7B8

Q36535275-5B26711D-F580-4FCF-B8E8-7FEA9ACD8C0F

Q36535275-6285B6D9-4E48-4094-8F3A-0A1C24EB137A

Q36535275-668DCCDE-23D8-41F8-99F4-2B6B8D619223

Q36535275-723F1826-E8CB-42A0-97CF-C1F3C5BC903B

P2860

Q36535275-02F7A4BC-BA7F-42CA-89AF-74B0E2BF0B88

Q36535275-057EF9DB-8197-4C5E-8708-DFAC3DD72883

Q36535275-1A98EF30-1561-493D-B9AE-15100E2782A1

Q36535275-1AEDB21D-C71F-4537-B22C-41D6ED0D871A

Q36535275-1B496046-DAC4-4D58-AB76-70EDDB16A12F

Q36535275-20ECB45F-DE7C-448D-88DE-FA90993B45ED

Q36535275-21DC06D1-6F20-4CDD-B60A-CF3EC953BF90

Q36535275-26B77382-4A07-41A4-95D9-ECA21EB0E36A

Q36535275-270FF534-C0C0-48A5-BC14-5E37D011A33A

Q36535275-27153E5B-EBE0-44B6-9A27-51A3DB3167D6

P304

Q36535275-B9B0B85B-2FFE-4280-ADDB-9F97E9E2BC80

P31

Q36535275-521F4BE0-7F54-4FE4-A524-D65172EC2C8D

P356

Q36535275-F1ACA9BE-143F-48B7-A0AB-109FD2BA5B16

P433

Q36535275-643821A3-6860-4676-9CC2-9D79A2855966

P478

Q36535275-F2C26D43-8C18-452C-B9C7-EF40C10B0750

P50

Q36535275-60BADFA9-12A5-4704-9C9F-C044D945DB57

Q36535275-7009267C-CF08-490C-8F16-B25FFB2DDFD6

Q36535275-D090A0BC-1D93-45C4-944A-CB21B41E4920

Q36535275-F5229BF9-C4E6-4948-A8FD-FDD6F30F0134

P577

Q36535275-3CCB494A-768A-4E87-9BA8-1286B81177CE

P698

Q36535275-7897FC60-B679-4761-8777-E986BAF56F0D

P921

Q36535275-C1E91C7F-0DD1-40C1-9923-D8AFDFA2859F

P932

Q36535275-8D5294A9-4447-42F0-81D5-298234561A23

P356

P1433

Annals of Neurology

P1476

Tau positron emission tomographic imaging in aging and early Alzheimer disease

@en

P2093

Bradford Dickerson

http://www.w3.org/2001/XMLSchema#string

Daniel Yokell

http://www.w3.org/2001/XMLSchema#string

Dorene Rentz

http://www.w3.org/2001/XMLSchema#string

Elizabeth Mormino

http://www.w3.org/2001/XMLSchema#string

Gad Marshall

http://www.w3.org/2001/XMLSchema#string

J Alex Becker

http://www.w3.org/2001/XMLSchema#string

Jasmeer Chhatwal

http://www.w3.org/2001/XMLSchema#string

Jonathan Alverio

http://www.w3.org/2001/XMLSchema#string

Kate Papp

http://www.w3.org/2001/XMLSchema#string

Keith A Johnson

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Tau imaging: early progress and future directions

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Development and validation of a geriatric depression screening scale: a preliminary report

The Clinical Dementia Rating (CDR): current version and scoring rules

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease.

Disruption of functional connectivity in clinically normal older adults harboring amyloid burden.

P304

110-119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.24546

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Aaron P. Schultz

P577

2015-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26505746

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4738026

http://www.w3.org/2001/XMLSchema#string